CHAIR
:
SPEAKER
(S):
Elmar Burchardt, PhD, MD, Vice President, Medical Affairs , Aastrom Biosciences, Inc
Robert Deans, Athersys, Inc
Thomas Okarma, PhD, MD, President, Director & CEO Geron CorporationPresident, Director & CEO Geron CorporationPresident, Director & CEO Geron CorporationPresident, Director & CEO Geron CorporationPresident, Director & CEO Geron CorporationPresident, Director & CEO , Geron Corporation
Bruce Wentworth, PhD, Director of Research , Genzyme Corporation
Description
"Show that cell therapy has reached the point of clinical application with a number of types of cells and hypotheses on how these cells can treat chronic heart disease. This session will review the area and discuss near-term prospects for new products."
Objective1:Give an overview of the promise of stem cell therapy for CV disease.
Objective2:Compare and contrast the different kinds of cells, including myoblast cells, bone marrow-derived cells and putative cardiomyocyte precursor cells.
Objective3:Highlight progress and potential for new products.